Standard BioTools Inc

In this Stage 4 decline, price has broken key support with a Support Failure pattern, and short-term and long-term trends remain down. Despite extreme oversold conditions, there are no signs of stabilization or institutional demand, with declining EMAs acting as resistance. Execution posture is bearish with the medium-term tradable side permitting a sell into rallies. Given unfavorable timing conditions for entering new bearish positions, execution should occur now on any relief bounce into EMAs or resistance areas.

• ↑110% upside to $1.35 consensus target from $0.64 current price.
• ↑Pipeline of innovative bio-tools may expand market share.
• ↓Negative earnings yield and profitability indicate weak return generation.